Burkitt lymphoma is a cancer of the lymphatic system, which develops from abnormal B lymphocytes and is characterized by rapid growth. Burkitt lymphoma usually causes lymph node enlargement in various parts of the body, including spleen, liver, bone marrow, and central nervous system. Burkitt lymphoma is a type of high-grade non-Hodgkin lymphoma (NHL). The World Health Organization has classified Burkitt lymphoma as an endemic that affects children in Africa aged 4-7 years, sporadic that occurs globally, and immunodeficiency-associated type that affects people suffering from HIV/AIDS. According to the survey by Cancer Therapy Advisor, Burkitt lymphoma accounts for 30% of pediatric lymphomas and less than 1% of lymphoma cases in adults, especially with a weakened immune system globally. Several cellular therapies are being developed, such as T cell therapy and CAR T cell therapy that use the patient’s own T cells to attack non-Hodgkin's lymphoma cells.

Market Dynamics

Rising incidence HIV is expected to augment growth of the Burkitt lymphoma treatment market, as Burkitt lymphoma is an AIDS-defining cancer that is expected to occur more frequently in people suffering from HIV than in the general population. According to the Burkitt Lymphoma Society, the condition accounts for an around 40% of all childhood non Hodgkin lymphoma patients worldwide. It also accounts for as many as 40% of all non-Hodgkin lymphomas in HIV/AIDS patients. Also, according to the Cancer Therapy Advisor, Burkitt lymphoma (BL) is the most common pediatric cancer with the disease incidence being 2-3 times higher in sub-Saharan Africa, with an estimated incidence of 3–6 cases per 100,000 children per year. The disease is termed as endemic Burkitt lymphoma, where a majority of cases are related to Epstein-Barr virus (EBV).

Moreover, various government and non-government organizations are undertaking research initiatives to launch efficient treatments and create awareness about the rare disease. For instance, the National Cancer Institute initiated the Burkitt Lymphoma Genome Sequencing Project (BLGSP) to explore potential genetic changes in patients suffering from Burkitt lymphoma (BL) that could lead to better prevention, detection, and treatment of this rare and aggressive cancer. Moreover, researchers at Forgarty International Center and National Cancer Institute are working together to address global health needs related to various cancer types, including Burkitt lymphoma. Non-profit organization such as Burkitt Lymphoma Society supports and connects patients and caregivers by connecting the patients who have received efficient care for Burkitt lymphoma, thus providing information and creating awareness about the rare medical condition. Also, in 2017, the Lymphoma Research Foundation granted US$ 700,000 to funding innovative research that serves education programs, outreach initiatives, and patient services, thus accelerating the burkitt lymphoma treatment market growth.

The presence of potential therapies for the prevention of Burkitt lymphoma is expected to augment the market growth over the forecast period. For instance, Viracta Therapeutics, Inc., initiated Phase 1 b/2 trial for Tractinostat in combination with Valganciclovir indicated for Epstein-Barr virus-positive (EBV+) lymphomas. According to the Cancer Research UK, 2015, around 200,000 new cases and over 140,000 deaths are estimated to be recorded each year due to EBV-associated cancers. Also, the National Cancer Institute initiated Phase 1 clinical trials for antibody therapy, directed against CD19- blinatumomab, a recombinant bispecific antibody in combination with Lenalidomide with Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL).

Moreover, the FDA approved a radioimmunotherapy named Zevalin (Ibritumomab tiuxetan) in combination with a radioactive substance linked to a monoclonal antibody named rituximab, to treat patients suffering from certain types of non-Hodgkin lymphoma, including Burkitt lymphoma.

Regional Dynamics

Regional segmentation of the global Burkitt lymphoma treatment market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global Burkitt lymphoma treatment market over the forecast period, owing to rising prevalence of lymphoma over the forecast period. According to the survey conducted by WebMD, LLC, 2015, around 1,200 people are diagnosed each year, of which 59% patients are aged 40 years and above in the U.S. Moreover, Burkitt lymphoma shows higher prevalence among HIV infected patients.

The Burkitt lymphoma treatment market in Europe is expected to witness high growth, owing to increasing prevalence of sporadic form of Burkitt lymphoma in the U.K. According to the survey by Lymphoma Action Organization, 2015, around 210 people are affected by Burkitt lymphoma every year in the U.K.

Competitive Analysis

Key players in this market are offering products to cater to the rising unmet needs of patients suffering from relapsed or refractory Burkitt lymphoma. For instance, Servier, in collaboration with Pfizer Inc., initiated Phase 1 study in 2015 for gene-edited allogeneic CAR19 T-cells (UCART19) to treat relapsed/ refractory acute lymphoblastic leukemia (ALL) in pediatric patients.

Key players operating in the global Burkitt lymphoma treatment market include Novartis AG, Sanofi Pasteur, Eisai Inc., Cellerant Therapeutics, Inc., Pfizer, Inc., Merck KGaA, Seattle Genetics, Inc., Karyopharm Therapeutics, Inc., Boehringer Ingelheim GmbH, and AbbVie Inc.

Market Taxonomy

On the basis of therapy type, the global Burkitt lymphoma treatment market is segmented into: